Identification of markers of prostate cancer progression using candidate gene expression
Identification of markers of prostate cancer progression using candidate gene expression
Background: Metastatic prostate cancer (PCa) has no curative treatment options. Some forms of PCa are indolent and slow growing, while others metastasise quickly and may prove fatal within a very short time. The basis of this variable prognosis is poorly understood, despite considerable research. The aim of this study was to identify markers associated with the progression of PCa.
Methods: Artificial neuronal network analysis combined with data from literature and previous work produced a panel of putative PCa progression markers, which were used in a transcriptomic analysis of 29 radical prostatectomy samples and correlated with clinical outcome.
Results: Statistical analysis yielded seven putative markers of PCa progression, ANPEP, ABL1, PSCA, EFNA1, HSPB1, INMT and TRIP13. Two data transformation methods were utilised with only markers that were significant in both selected for further analysis. ANPEP and EFNA1 were significantly correlated with Gleason score. Models of progression co-utilising markers ANPEP and ABL1 or ANPEP and PSCA had the ability to correctly predict indolent or aggressive disease, based on Gleason score, in 89.7% and 86.2% of cases, respectively. Another model of TRIP13 expression in combination with preoperative PSA level and Gleason score was able to correctly predict recurrence in 85.7% of cases.
Conclusion: This proof of principle study demonstrates a novel association of carcinogenic and tumourigenic gene expression with PCa stage and prognosis.
taqman, qPCR, prostate cancer, ANPEP, ABL1, PSCA, TRIP13
157-165
Larkin, S.E.T.
73ffb031-2115-47e3-a62f-907d687d108f
Holmes, S.
db2aa9dc-9d10-4e3f-843f-40af0f562001
Cree, I.A.
032d4eb7-947d-492d-a49e-f47b02684ea9
Walker, T.
257f15bb-88f8-444c-8a54-baa6ae440470
Basketter, V.
0d0b9b4c-ff36-4d62-8da0-0d6f9a3c286d
Bickers, B.
1b26f983-91ae-4603-8c34-82c841a8c343
Harris, S.
19ea097b-df15-4f0f-be19-8ac42c190028
Garbis, Spiros D.
7067fd19-50c9-4d42-9611-f370289470bd
Townsend, P.A.
89300833-c898-4ae1-a3b2-03214c71da52
Aukim-Hastie, C.
318b782d-a299-4fee-bdc4-c437dabdce89
3 January 2012
Larkin, S.E.T.
73ffb031-2115-47e3-a62f-907d687d108f
Holmes, S.
db2aa9dc-9d10-4e3f-843f-40af0f562001
Cree, I.A.
032d4eb7-947d-492d-a49e-f47b02684ea9
Walker, T.
257f15bb-88f8-444c-8a54-baa6ae440470
Basketter, V.
0d0b9b4c-ff36-4d62-8da0-0d6f9a3c286d
Bickers, B.
1b26f983-91ae-4603-8c34-82c841a8c343
Harris, S.
19ea097b-df15-4f0f-be19-8ac42c190028
Garbis, Spiros D.
7067fd19-50c9-4d42-9611-f370289470bd
Townsend, P.A.
89300833-c898-4ae1-a3b2-03214c71da52
Aukim-Hastie, C.
318b782d-a299-4fee-bdc4-c437dabdce89
Larkin, S.E.T., Holmes, S., Cree, I.A., Walker, T., Basketter, V., Bickers, B., Harris, S., Garbis, Spiros D., Townsend, P.A. and Aukim-Hastie, C.
(2012)
Identification of markers of prostate cancer progression using candidate gene expression.
British Journal of Cancer, 106 (1), .
(doi:10.1038/bjc.2011.490).
(PMID:22075945)
Abstract
Background: Metastatic prostate cancer (PCa) has no curative treatment options. Some forms of PCa are indolent and slow growing, while others metastasise quickly and may prove fatal within a very short time. The basis of this variable prognosis is poorly understood, despite considerable research. The aim of this study was to identify markers associated with the progression of PCa.
Methods: Artificial neuronal network analysis combined with data from literature and previous work produced a panel of putative PCa progression markers, which were used in a transcriptomic analysis of 29 radical prostatectomy samples and correlated with clinical outcome.
Results: Statistical analysis yielded seven putative markers of PCa progression, ANPEP, ABL1, PSCA, EFNA1, HSPB1, INMT and TRIP13. Two data transformation methods were utilised with only markers that were significant in both selected for further analysis. ANPEP and EFNA1 were significantly correlated with Gleason score. Models of progression co-utilising markers ANPEP and ABL1 or ANPEP and PSCA had the ability to correctly predict indolent or aggressive disease, based on Gleason score, in 89.7% and 86.2% of cases, respectively. Another model of TRIP13 expression in combination with preoperative PSA level and Gleason score was able to correctly predict recurrence in 85.7% of cases.
Conclusion: This proof of principle study demonstrates a novel association of carcinogenic and tumourigenic gene expression with PCa stage and prognosis.
This record has no associated files available for download.
More information
e-pub ahead of print date: 10 November 2011
Published date: 3 January 2012
Keywords:
taqman, qPCR, prostate cancer, ANPEP, ABL1, PSCA, TRIP13
Organisations:
Cancer Sciences, Primary Care & Population Sciences
Identifiers
Local EPrints ID: 203411
URI: http://eprints.soton.ac.uk/id/eprint/203411
ISSN: 0007-0920
PURE UUID: 67bfb9bb-6c85-459e-a1aa-603d1bc61c7c
Catalogue record
Date deposited: 16 Nov 2011 12:21
Last modified: 14 Mar 2024 04:28
Export record
Altmetrics
Contributors
Author:
S.E.T. Larkin
Author:
S. Holmes
Author:
I.A. Cree
Author:
T. Walker
Author:
V. Basketter
Author:
B. Bickers
Author:
Spiros D. Garbis
Author:
P.A. Townsend
Author:
C. Aukim-Hastie
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics